Clinical Trial Update: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of UGN-301 in patients with recurrent non-muscle invasive bladder cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Carcinoma in Situ of the Bladder
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• UGN-301

Snippet

Sponsor: UroGen Pharma Ltd. | Conditions: Non-muscle Invasive Bladder Cancer, NMIBC | Phase 1 | Status: COMPLETED